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Word count 999.  
Introduction. As the global pandemic of severe acute respiratory syndrome coronavirus 2 
(SARS-CoV2) continues, nuances of the disease it precipitates in humans continue to 
emerge.  Following early reports of presentation with gastro-intestinal-type symptoms in 
China1 and Italy2, a group from Wuhan reported a series of 9 patients with purported 
pancreatic injury in the context of SARS-CoV2 infection3, but did not provide robust 
evidence for pancreatitis relying on mild hyperamylasaemia alone. Current international 
consensus for a diagnosis of acute pancreatitis requires two of the following three features: 1) 
Abdominal pain consistent with pancreatitis; 2) Serum amylase/lipase greater than 3 times 
the upper limit of normal and 3) Characteristic findings on cross sectional imaging4. Simply 
put, there are too many causes for hyperamylasaemia in the context of systemic illness, with 
or without SARS-CoV2, for its use in isolation as a marker of pancreatic injury. None the 
less, we report here 5 cases of atypical but proven acute pancreatitis in the context of SARS-
CoV2 infection. 
 
Methods. This review was registered with the Liverpool University Hospitals NHS 
Foundation Trust audit department (ID TA0002744). Cases were identified searching 
admission diagnoses (ICD10 K85) or radiology requests and reports for ‘acute pancreatitis’. 
SARS-CoV2 was diagnosed when either swabs were positive on rapid PCR (VIASURETM) 
or patients had radiological evidence of SARS-CoV2 infection (supplementary figure 1). 
Cases with pre-existing pancreatic pathology or where the etiology was clearly non-SARS-
CoV2 related were excluded. Data extracted from patient and radiology records was used to 
calculate clinical scores as well as hepatic steatosis estimates by analysis of contrast-
enhanced computerised tomography (CECT) images as previously described5. Imaging 
findings were re-reported by an expert pancreatic radiologist.  
 
Results. Between 14th of March and 30th of April 2020, 35 patients with acute pancreatitis 
were assessed at the Royal Liverpool University Hospital. 25 patients were negative for 
SARS-CoV2 and were excluded. Of the remaining 10 patients who were deemed positive for 
SARS-CoV2 a further 5 were excluded because they presented with a clearly defined 
etiology (e.g. choledocholithiasis). The remaining 5 patients, all with SARS-CoV2, presented 
atypically yet homogenously with a distinct metabolic-pancreatitis phenotype. These 5 
patients form the cohort subsequently discussed (supplementary figure 1). 
 
All 5 patients were young adult males (median age 42 years; IQR 15) who were either 
overweight or obese (median BMI 30; IQR 6.7). Serum amylase was elevated but non-
diagnostic in all cases (median 149 U/L; IQR 238), contrast-enhanced abdominal CT (CECT) 
was used to confirm the diagnosis. Patients had no sonographic evidence of gallstones on this 
admission. No patient had known cardiovascular disease. On admission patients had evidence 
of metabolic distress; median (IQR) levels of triglycerides and glucose were 2.7 (18.2) 
mmol/L and 10 (8.6) mmol/L respectively. 1 patient had sustained ethanol use without 
hypertriglyceridemia or hyperglycaemia, but importantly had no prior pancreas symptoms. 1 
patient had a long term medication history (Atorvastatin and Sertraline) again without prior 
pancreatitis symptoms. However, in all patients, CECT showed transient moderate to severe 
hepatic steatosis (<104 HU), which rapidly regressed in patients for whom follow-up CECT 
was available. Median attenuation (IQR) on admission was -3.5 (55.8) HU with a median 
(IQR) improvement at 7 days of  31.12 HU (3.1). The pattern of pancreatic inflammation was 
similarly unusual in these patients: Mild pancreatic edema without significant pancreatic or 
peripancreatic necrosis, with distinct duodenal/periduodenal inflammation involving the 
second and third part of the duodenum. Radiological findings were accompanied by a 
profound systemic inflammatory response (1-2 SIRS criteria on admission; 2-4 after 48 
hours) and dramatic elevation of C-reactive protein (median 31 mg/L, IQR 141 on admission 
vs. 485 mg/L, IQR 286.5 after 48 hours). 
 
All patients were treated with intra-venous fluids; 3 out of 5 received insulin and/or fibrate 
therapy. Abdominal pain was managed with opiate analgesia and all patients were tolerant of 
oral diet from admission. 4 out of 5 patients with CT findings suggestive of pneumonitis 
received broad-spectrum intra-venous antibiotics. None of the patients received 
corticosteroids and none required organ support, beyond low-flow oxygen, or admission to a 
level 2/3 care setting. Thus, all were classed as moderate pancreatitis based on the presence 
of acute fluid collections alone. 2 Patients required pancreatic enzyme replacement therapy to 
control their abdominal pain and steatorrhea, indicating a true exocrine component to their 
disease. Median length of stay (range) was 14 days (6-16).  
 
Discussion. Despite the dramatic way these 5 patients presented, with multiple metrics 
predictive of severe disease, their pathway was much more benign than anticipated and not 
dissimilar from a typical attack of moderate pancreatitis. We therefore propose the 
combination of male sex, abdominal pain, metabolic stress and CT-findings of predominantly 
pancreatico-duodenal inflammation with steatosis represent a distinct subset of pancreatitis in 
patients infected with SARS-CoV2. Furthermore, we postulate that the endocrine pancreas is 
particularly vulnerable to this infection. While we cannot deduce causality based on data 
presented here, we note that the human pancreas is known to express high concentrations of 
angiotensin-converting enzyme 2 (ACE2)6, especially (but not exclusively) in the pancreatic 
islets where binding to SARS-CoV1 has been shown to induce acute diabetes7. Persons with 
pre-existing metabolic syndrome, even if not formally diagnosed, may be at particular risk in 
light of the high BMIs and HbA1c in our case series. 
 Acute pancreatitis secondary to hypertriglyceridemia is uncommon in Western populations 
and more often associated with severe disease, organ failure and death than other etiologies8. 
None of the patients presented here had transient or persistent organ failure and the main 
reason for the prolonged length of stay in all cases was poor diabetic control or persistent 
elevation of serum inflammatory markers. We speculate that due to the low levels of free 
pancreatic enzymes (as evidenced by near normal levels of circulating pancreatic amylase), 
toxic lipolysis does not occur, and the liver is able to absorb the majority of triglycerides 
resulting in the changes in hepatic steatosis observed. These patients likely represent the 
severe end of the pancreatopathy spectrum, but transient dyslipidaemias and impaired 
glucose tolerance may be common in SARS-CoV2 patients and warrant further investigation. 
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Figure1. Flow Diagram. * A diagnosis was made by either a rapid PCR (VIASURETM) or radiological evidence of
SARS-CoV2, the COVID CT score is based on the British Society of Thoracic Imaging criteria where changes are
classed as ‘probable’ where there is >70 % confidence of COVID infection1. Patients excluded with gall stones had
either biliary dilatation, abnormal liver function tests or confirmed ductal stones. Patients excluded with ethanol use
had a history of stable chronic alcohol use/abuse, with/without recent binge, with/without pre-existing
neurological/liver/pancreas injury. Patients excluded with pre-existing attacks had Recurrent acute or acute-on-chronic
pancreatitis with at least one attack prior to Nov 2019. Patients excluded with post ERCP pancreatitis, 1 suspected
gallstones, but trawl negative, 1 head of pancreas mass/stent). **Patients negative for SARS-CoV2 and excluded for
other reasons had Gallstones excluded on ultrasound or MRI; had no history of significant alcohol intake OR recently
reducing alcohol intake in the absence of pre-existing alcohol-related organ damage.
1[https://www.bsti.org.uk/media/resources/files/BSTI_COVID-19_Radiology_Guidance_version_2_16.03.20.pdf].
All 5 patients included 
for further analysis
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Summary statistic 
   1 2 3 4 5  Median IQR 
    
D
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Age 
 
29 41 42 47 53 
 
42 15 
Sex 
 
M M M M M 
 
- - 
BMI 
 
32.9 35.8 29.7 25.7 30 
 
30 6.7 
Ethnicity 
 
Other Asian White British White British White British Other White - - 
          
HTN 
 
No No No No No 
 
- - 
DM 
 
No No No No No 
 
- - 
Respiratory 
Disease  
No No Asthma No No 
 
- - 
Charlston 
Index  
0 0 0 0 1 
 
- - 
 
          
C
O
V
ID
 
st
a
tu
s CT score 
 
Normal 
(CVCT0) 
Classic/Probable 
(CVCT1) 
Classic/Probable 
(CVCT1) 
Non-COVID 
(CVCT3) 
Classic/Probable 
(CVCT1) 
Throat 
swab  
Positive Negative Unknown Positive Negative 
   
         
Median IQR 
P
a
n
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e
a
ti
ti
s 
d
ia
g
n
o
st
ic
s 
Typical 
pain  
Yes Yes Yes Yes Yes 
 
- - 
Amylase 
(U/L)  
77 149 378 211 36 
 
149 238 
Amylase timing  
(hours after pain) 
27 20 6 16 23 
 
20 14 
CT on 
admission  
Pancreatitis Pancreatitis Pancreatitis Pancreatitis Pancreatitis - - 
         
Median IQR 
P
a
n
cr
e
a
ti
ti
s 
ri
sk
 f
a
ct
o
rs
 
Gallstones 
(Ultrasound) 
No No No No No 
 
- - 
Alcohol intake 
(g / week) 
0 80 400 50 0 
 
50 240 
Smoker 
 
Never Yes Never Ex Yes 
 
- - 
Medication 
 
None None 
Omeprazole; 
Thiamine; 
Hydroxycobalamin 
Atorvastatin; 
Sertraline 
None 
 
- - 
         
Median IQR 
C
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l 
ch
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e
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s 
o
f 
p
a
n
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e
a
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s 
SIRS 
(admission)  
2 2 1 2 2 
 
- - 
SIRS  
(48h peak)  
4 2 3 4 2 
 
- - 
CRP 
(admission)  
258 37 5 8 31 
 
31 141 
CRP 
(peak)  
597 550 292 485 282 
 
485 286.5 
Peak CRP time 
(days from 
admission) 
0 2 9 2 0 
 
2 5.5 
Organ 
failure  
No No No No No 
 
- - 
Activity index 
(admission) 
 250 220 - 245 145  232.5 85 
Activity index 
(48 h)  
205 150 - 175 25 
 
162.5 141.3 
        
Median IQR 
Im
a
g
in
g
 f
in
d
in
g
s Focus of 
inflammation 
Periduodenal 
(D1-D4) and 
pancreatic 
head 
Periduodenal 
(D2-D3) and 
pancreatic head 
Periduodenal  
(D1-3) and 
peripancreatic 
Duodenal 
thickening  
(D2-3) and 
peripancreatic 
Duodenum 
spared; 
peripancreatic 
Peripancreatic 
necrosis 
No No No No No 
 
- - 
Pancreatic 
necrosis 
None None None 
Pancreatic tail 
(<30 %) 
None 
 
- - 
Acute fluid 
collections 
Paraduodenal None Peripancreatic Pancreatic tail Paraduodenal 
 
Modified 
Balthasar score 
6 2 4 8 4 
 
4 4 
         
Median IQR 
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rs
 
New onset 
diabetes 
Yes Yes No No Yes 
 
- - 
Glucose on 
admission 
(mmol/L ; mg/dL) 
14.3 ; 257.4 16.6 ; 298.8 7.9 ; 142.2 5.9 ; 106.2 10 ; 180 
 
10 ; 180 8.6 ; 154.8 
HbA1c 
(IFCCmmol
/mol) 
 
86 - - 36 47 
 
- - 
Urinalysis on 
admission 
Glucose 4+ 
Glucose +; 
Ketones + 
- - - 
 
- - 
Insulin 
therapy  
Yes Yes No No No 
 
- - 
Triglycerides on 
admission 
(mmol/L ; mg/L) 
30.9 ; 2740 8.4 ; 743 1.65 ; 146 2.7 ; 239 1.3 ; 115 
 
2.7 ; 239 18.2 ; 1610 
Hepatic steatosis 
(admission; HU) 
18.0 -46.7 -18.1 11.1 - 
 
-3.5 55.8 
Hepatic steatosis 
(7 days; HU) 
50.6 -15.6 8.30 42.2 - 
 
25.2 50.1 
 ∆Hepatic steatosis 32.7 31.1 26.4 31.1 -  31.1 3.1 
 
        
Median IQR 
O
u
tc
o
m
e
 
p
a
ra
m
e
te
rs
 
Severity of 
pancreatitis 
Moderate Moderate Moderate Moderate Moderate 
 
- - 
LOS (days) 
 
16 14 16 12 6 
 
14 7 
Intervention No No No No No 
 
- - 
New therapy on 
discharge 
Insulin; PERT; 
Fibrate 
Insulin No PERT; Fibrate No 
 
- - 
 
 
Table 1. Clinical characteristics of patients with acute pancreatitis in the context of COVID19 infection. 
All summary parameters are median (IQR). Ethnicity labels are those used by the Office of National Statistics of 
the UK. COVID CT score is based on the British Society of Thoracic Imaging criteria where changes are 
classed as ‘probable’ where there is >70 % confidence of COVID infection. SIRS score is calculated by 
presence of the following – Temperature >38oC or <36oC; Heart rate >90; Respiratory rate >20 or PaCO2 < 32 
mmHg; WBC > 12000/mm3.  Organ failure is defined as a SOFA score of 2 or more. Pancreatic activity index is 
a composite score including organ failure, tolerance to oral diet, SIRS, abdominal pain and intra-venous 
morphine equivalent dose on any given day. Hepatic steatosis is based on CECT image evaluation as previously 
reported. Severity of pancreatitis is defined by the Revised Atlanta Classification 2012. 
 
